# Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency

> **NCT04594668** · PHASE2 · UNKNOWN · sponsor: **University of Aarhus** · enrollment: 46 (estimated)

## Conditions studied

- ARDS, Human
- COVID

## Interventions

- **DRUG:** Senicapoc

## Key facts

- **NCT ID:** NCT04594668
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-24
- **Primary completion:** 2021-04-24
- **Final completion:** 2021-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2020-10-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594668, "Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04594668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*